Dewhurst Martin William 4

What Happened

• Martin W. Dewhurst, a director of Turn Therapeutics (TTRX), was granted a derivative award covering 71,666 shares on June 4, 2026. The filing reports an acquisition code "A" at $0.00 (no cash paid reported) and lists the instrument as a derivative (option) rather than immediate common shares.

Key Details

• Transaction date: 2026-06-04; Form 4 filed 2026-06-08 (timely filing; no late-file indicator in the information provided).
• Amount: 71,666 share-equivalents granted; reported price $0.00 and reported value $0 at grant.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Footnote: The option vests in 12 equal monthly installments on the last day of each month, beginning June 30, 2026, subject to continued employment and the Issuer’s 2025 Omnibus Incentive Plan.

Context

• This is a grant of a derivative award (an option) that vests over time — not an immediate open-market purchase. No immediate proceeds or sales are indicated. Such awards are common for directors and are compensation-related; they do not necessarily signal immediate buying or selling intent.